312 related articles for article (PubMed ID: 27414060)
1. Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.
K Singh V; Werner S; Hackstein H; Lennerz V; Reiter A; Wölfel T; Damm-Welk C; Woessmann W
Clin Exp Immunol; 2016 Oct; 186(1):96-105. PubMed ID: 27414060
[TBL] [Abstract][Full Text] [Related]
2. NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma.
Singh VK; Werner S; Schwalm S; Lennerz V; Ruf S; Stadler S; Hackstein H; Reiter A; Wölfel T; Damm-Welk C; Woessmann W
Oncoimmunology; 2019; 8(9):e1625688. PubMed ID: 31428523
[TBL] [Abstract][Full Text] [Related]
3. B and CTL responses to the ALK protein in patients with ALK-positive ALCL.
Ait-Tahar K; Cerundolo V; Banham AH; Hatton C; Blanchard T; Kusec R; Becker M; Smith GL; Pulford K
Int J Cancer; 2006 Feb; 118(3):688-95. PubMed ID: 16114011
[TBL] [Abstract][Full Text] [Related]
4. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.
Passoni L; Scardino A; Bertazzoli C; Gallo B; Coluccia AM; Lemonnier FA; Kosmatopoulos K; Gambacorti-Passerini C
Blood; 2002 Mar; 99(6):2100-6. PubMed ID: 11877285
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
6. Epitope mapping of anti-ALK antibodies in children with anaplastic large cell lymphoma.
Knörr F; Weber S; Singh VK; Pulford K; Reiter A; Woessmann W; Damm-Welk C
Clin Immunol; 2018 Oct; 195():77-81. PubMed ID: 30077013
[TBL] [Abstract][Full Text] [Related]
7. Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.
Wu F; Wang P; Zhang J; Young LC; Lai R; Li L
Mol Cell Proteomics; 2010 Jul; 9(7):1616-32. PubMed ID: 20393185
[TBL] [Abstract][Full Text] [Related]
8. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
[TBL] [Abstract][Full Text] [Related]
9. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
10. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma.
Iijima-Yamashita Y; Mori T; Nakazawa A; Fukano R; Takimoto T; Tsurusawa M; Kobayashi R; Horibe K
Int J Hematol; 2018 Feb; 107(2):244-250. PubMed ID: 29030834
[TBL] [Abstract][Full Text] [Related]
12. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
[TBL] [Abstract][Full Text] [Related]
13. In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas.
Passoni L; Gallo B; Biganzoli E; Stefanoni R; Massimino M; Di Nicola M; Gianni AM; Gambacorti-Passerini C
Haematologica; 2006 Jan; 91(1):48-55. PubMed ID: 16434370
[TBL] [Abstract][Full Text] [Related]
14. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
15. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma.
Pulford K; Falini B; Banham AH; Codrington D; Roberton H; Hatton C; Mason DY
Blood; 2000 Aug; 96(4):1605-7. PubMed ID: 10942417
[TBL] [Abstract][Full Text] [Related]
16. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic lymphoma kinase proteins and malignancy.
Pulford K; Morris SW; Mason DY
Curr Opin Hematol; 2001 Jul; 8(4):231-6. PubMed ID: 11561161
[TBL] [Abstract][Full Text] [Related]
18. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.
Pulford K; Lamant L; Morris SW; Butler LH; Wood KM; Stroud D; Delsol G; Mason DY
Blood; 1997 Feb; 89(4):1394-404. PubMed ID: 9028963
[TBL] [Abstract][Full Text] [Related]
19. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis.
Mussolin L; Damm-Welk C; Pillon M; Zimmermann M; Franceschetto G; Pulford K; Reiter A; Rosolen A; Woessmann W
Leukemia; 2013 Feb; 27(2):416-22. PubMed ID: 22907048
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
